The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
In addition to developing new medicines, the company achieved several technological advances, including the automation of its production facilities. Lilly was also an innovator in pill capsule manufacturing. It was among the first manufacturers to insert medications into empty gelatin capsules, which provided a more exact dosage. Lilly manufactured capsules for its own needs and sold its excess capacity to others. In 1917, Scientific American described Lilly as "the largest capsule factory in the world" and reported that the company was "capable of producing 2.5 million capsules a day". One of Lilly's early innovations was fruit flavoring for medicines and sugar-coated pills to make their medicines easier to swallow. Over the next few years, the company created tens of millions of capsules and pills annually. Other advances improved plant efficiency and eliminated production errors. In 1909, Eli Lilly, grandson of the company's founder, introduced a method for blueprinting manufacturing tickets, which created multiples copies of a drug formula and helped eliminate manufacturing and transcription errors. In 1920, Josiah hired biochemist George Henry Alexander Clowes as a research chemist; Clowes was promoted to director of biochemical research the following year. In the 1920s, Eli introduced the new concept of straight-line production to the pharmaceutical industry, where raw materials entered at one end of the facility and the finished product came out the other end, in the company's manufacturing process.
Like many other biologically active substances, norepinephrine exerts its effects by binding to and activating receptors located on the surface of cells. Two broad families of norepinephrine receptors have been identified, known as alpha and beta-adrenergic receptors. Alpha receptors are divided into subtypes α1 and α2; beta receptors into subtypes β1, β2, and β3. All of these function as G protein-coupled receptors, meaning that they exert their effects via a complex second messenger system. Alpha-2 receptors usually have inhibitory effects, but many are located pre-synaptically (i.e., on the surface of the cells that release norepinephrine), so the net effect of alpha-2 activation is often a decrease in the amount of norepinephrine released. Alpha-1 receptors and all three types of beta receptors usually have excitatory effects.
=== Medical use === PABA and its salts are used in nutritional epidemiological studies to assess the completeness of 24-hour urine collection for the determination of urinary sodium, potassium, or nitrogen levels. The potassium salt (potassium paraaminobenzoate, "aminobenzoate potassium") is used as a drug against fibrotic skin disorders, such as Peyronie's disease, under the brand name Potaba. There is a lack of strong evidence. It is believed to work by inhibiting fibroblast glycosaminoglycan secretion and stabilizing monoamine oxidase A activity. PABA is also occasionally used in pill form by sufferers of irritable bowel syndrome to treat its associated gastrointestinal symptoms. PABA derivatives have also been proposed to function as acetylcholinesterase inhibitors in diseases that cause deficient cholinergic systems, such as Alzheimer's disease.
=== Mitral stenosis === Chest x-ray in mitral stenosis will typically show an enlarged left atrium, and may show dilation of the pulmonary veins. ECG can show left atrial enlargement, due to increased pressures in the left atrium. Echocardiography is helpful in determining the severity of the disease by estimating the pulmonary artery systolic pressure. This test can also show leaflet calcification and the pressure gradient over the mitral valve. Severe mitral stenosis is defined as a mitral valve area <1.5 cm2. Progressive mitral stenosis has a normal valve area but will have increased flow velocity across the mitral valve.
== Transmission == The feline panleukopenia virus is considered ubiquitous, meaning it is in virtually every place that is not regularly disinfected. The infection is highly contagious among unvaccinated cats. Antibodies against FPLV, produced by the adaptive immune system, play an important role in the feline response to the virus. Maternally-derived antibodies (MDA) efficiently protect kittens from fatal infection. This passively acquired immunity is later replaced by an active immune response obtained by vaccination or as a consequence of a natural infection. In kittens, the period of greatest susceptibility to infection is when maternal antibodies are absent, or waning, and vaccine-induced immunity has not yet fully developed. Free-roaming cats are thought to be exposed to the virus during their first year of life. Those that develop a subclinical infection or survive acute illness mount a robust, long-lasting, protective immune response. An infected cat sheds large amounts of virus in all body secretions including feces, vomit, urine, saliva, and mucus during the acute phase of illness. It can continue to shed the virus for as long as six weeks after recovery. Subclinically ill cats can also shed the virus in body secretions. The virus can be carried or transferred on an infected object (such as bedding, food dishes, fur) or by other animals, fleas, and humans (see: fomites). It persists long after evidence of the original body secretion has faded away, and can be transported long distances.
Sources: en.wikipedia.org
=== Behavioral immunity === When the mealworms feed on infected rodent feces, they may consume the eggs of the parasitic tapeworm Hymenolepis diminuta. Infected male beetles pay a higher reproductive cost than the female beetles. T. molitor displays behavioral immunity when exposed to H. diminuta, shown by how the infected males develop an avoidance behavior for feces that harbor the tapeworm, which decreases their probability of coming into contact with the tapeworm in the future. The female mealworm beetles develop a qualitative resistance through mate choice, as they are able to evaluate male immunocompetence through pheromone signaling, allowing them to choose the more immunologically fit males as mates. This also reduces the probability of the females being infected by their mates, and may cause them to pass on an enhanced level of immunocompetence to their offspring. Another way mealworms may display behavioral immunity is how they may tolerate infections by limiting negative effects on their reproductive success. For example, mealworm beetles tolerate a high number of cysticercoids of H. diminuta at the expense of their own fitness and longevity. Conversely, males produce enhanced spermatophores containing superior nuptial gifts; once transferred, these investments elevate female fecundity and fertilization success.
The NAS report described the level of lowest exposure from Greer et al. as a "no-observed-effect level" (NOEL). However, there was actually an effect at that level although not statistically significant largely due to small size of study population (four of seven subjects showed a slight decrease in iodide uptake). Reduced iodide uptake was not considered to be an adverse effect, even though it is a precursor to an adverse effect, hypothyroidism. Therefore, additional safety factors, would be necessary when extrapolating from the point of departure to the RfD. Consideration of data uncertainty was insufficient because the Greer, et al. study reflected only a 14-day exposure (=acute) to healthy adults and no additional safety factors were considered to protect sensitive subpopulations like for example, breastfeeding newborns. Although there has generally been consensus with the Greer et al. study, there has been no consensus with regard to developing a perchlorate RfD. One of the key differences results from how the point of departure is viewed (i.e., NOEL or "lowest-observed-adverse-effect level", LOAEL), or whether a benchmark dose should be used to derive the RfD. Defining the point of departure as a NOEL or LOAEL has implications when it comes to applying appropriate safety factors to the point of departure to derive the RfD. In early 2006, EPA issued a "Cleanup Guidance" and recommended a Drinking Water Equivalent Level (DWEL) for perchlorate of 24.5 μg/L.
Noboa has adopted a militarized approach to crime in Ecuador, frequently invoking states of emergency, expanding the military role in internal security, weakened judicial institutions, and raising human rights concerns. Supporters say his approach has helped to fight crime. Critics say Noboa is an autocrat, and accuse him of human rights violations, centralization of power and undermining press freedom.
== Career == Aramwit's career started as a Formulator/Research Investigator at Pfizer Pharmaceutical Worldwide in the USA. She then served as the deputy director for International Affairs and Immigrant Workers at the Internal Security Operations Command in Thailand from April 2014 to 2017. Since then, she has been serving as the Acting Vice President on the President and Administrative Board, while concurrently holding the position of Director of Research Projects at Center of Excellence in Bioactive Resources for Innovative Clinical Applications (BRICA) and Dean of the Faculty of Pharmaceutical Sciences at the Department of Pharmacy Practice (PharmCU) at CU. Within these roles, she oversaw collaborations on nutritional supplements with Innobic (Asia) and TISTR, led skincare product development with CU Innovation Hub and UMI Deeptech, and contributed to StemAktiv's research, highlighting its potential in skincare and aging treatment with safe herbal extracts, while also overseeing CU's Faculty of Pharmaceutical Sciences signing an MOU with Mahidol University and another MOU with Degree Plus. In addition, she has been appointed as an adjunct professor in the Faculty of Pharmacy at the Silpakorn University in Thailand and a visiting professor at the Institute of Natural Medicine of the University of Toyama in Japan.
Sources: en.wikipedia.org
== Career and research == While a graduate student at the University of Iowa, Sherman also worked in the campus library and as a janitor in addition to his research assistant duties. In 1953, while working as a research associate in the university's Department of Urology, Sherman refined a process that had been developed in 1949 by A.S. Parkes and two British scientists, which involved the use of glycerol to preserve animal sperm during freezing and thawing. Combined with the glycerol method, Sherman introduced slow cooling and use of solid carbon dioxide as a refrigerant during storage. Sherman collaborated on these experiments with urologist Dr. Raymond Bunge, who arranged for Sherman to be hired in the urology department and who was affiliated with the university's new fertility clinic, which had opened in early 1952. Bunge and Sherman had met while Sherman was painting the former's house in another side job. In 1953, three patients at the clinic were impregnated using frozen sperm, with Dr. William Keettel, an obstetrician at the fertility clinic, overseeing the patients. The same year, Sherman established the first sperm cryobank in the world in Iowa City to assist these pregnancies. Bunge and Sherman published their findings first in the Proceedings of the Society for Experimental Biology and Medicine and later Nature magazine.
===== MeSH D08.811.682.732 – peroxidases ===== MeSH D08.811.682.732.332 – catalase MeSH D08.811.682.732.360 – chloride peroxidase MeSH D08.811.682.732.380 – cytochrome-c peroxidase MeSH D08.811.682.732.440 – eosinophil peroxidase MeSH D08.811.682.732.500 – glutathione peroxidase MeSH D08.811.682.732.512 – horseradish peroxidase MeSH D08.811.682.732.512.900 – wheat germ agglutinin-horseradish peroxidase conjugate MeSH D08.811.682.732.525 – iodide peroxidase MeSH D08.811.682.732.550 – lactoperoxidase MeSH D08.811.682.732.700 – peroxidase
The evolutionary role of opioid signalling in these behaviours was confirmed in dogs, chicks, and rats. Opioid receptors also have a role in mating behaviors. However, mu-opioid receptors do not just control social behaviour because they also make individuals feel relaxed in a wide range of other situations. Kappa- and delta-opioid receptors may be less associated with relaxation and analgesia because kappa-opioid receptor suppresses mu-opioid receptor activation, and delta-opioid receptor interacts differently with agonists and antagonists. Kappa-opioid receptors are involved in chronic anxiety's perceptual mobilization, whereas delta-opioid receptors induce action initiation, impulsivity, and behavioural mobilization. These differences led some researches to suggest that up- or down-regulations within three opioid receptors families are the basis of different dispositional emotionality seen in psychiatric disorders. Human-specific opioid-modulated cognitive features are not attributable to coding differences for receptors or ligands, which share 99% similarity with primates, but to regulatory changes in expression levels.
==== Cell fate specification ==== Cell fate specification or cell differentiation is a process where undifferentiated cells can become a more specialized cell type. Wnt signaling induces differentiation of pluripotent stem cells into mesoderm and endoderm progenitor cells. These progenitor cells further differentiate into cell types such as endothelial, cardiac and vascular smooth muscle lineages. Wnt signaling induces blood formation from stem cells. Specifically, Wnt3 leads to mesoderm committed cells with hematopoietic potential. Wnt1 antagonizes neural differentiation and is a major factor in self-renewal of neural stem cells. This allows for regeneration of nervous system cells, which is further evidence of a role in promoting neural stem cell proliferation. Wnt signaling is involved in germ cell determination, gut tissue specification, hair follicle development, lung tissue development, trunk neural crest cell differentiation, nephron development, ovary development and sex determination. Wnt signaling also antagonizes heart formation, and Wnt inhibition was shown to be a critical inducer of heart tissue during development, and small molecule Wnt inhibitors are routinely used to produce cardiomyocytes from pluripotent stem cells.
== Further reading == Alexander, Mark, and John Sparry. Jump Commander: In Combat with the 82nd Airborne in World War II. Philadelphia: Casemate, 2010. ISBN 1-935149-28-8 OCLC 506253036 Angress, Werner T. Witness to the Storm: A Jewish Journey from Nazi Berlin to the 82nd Airborne, 1920–1945. Durham, NC: Miriam Angress, 2012. ISBN 1-4774-5701-1 OCLC 804824030 Anzuoni, Robert P. I'm the 82nd Airborne Division!: A History of the All American Division in World War II After Action Reports. Atglen, PA : Schiffer Publishing, 2005. ISBN 0-7643-2347-4 OCLC 62555533 Anzuoni, Robert P. The All American: An Illustrated History of the 82nd Airborne Division, 1917 to the Present. Atglen, PA: Schiffer Pub, 2001. ISBN 0-7643-1321-5 OCLC 49935879 Barry, Robert F. Power Pack: The Dominican Republic, 1965–1966. Portsmouth, Va: Messenger, 1965. OCLC 6655474 Baugh, James Emory. From Skies of Blue: My Experiences with the Eighty-Second Airborne During World War II. New York: iUniverse, 2003. ISBN 0-595-74982-8 OCLC 64584040 Breuer, William B. Drop Zone, Sicily: Allied Airborne Strike, July 1943. Novato, CA: Presidio, 1983. ISBN 0-89141-196-8 OCLC 9945654 Burriss, T. Moffatt. Strike and Hold: A Memoir of the 82nd Airborne in World War II. Washington, D.C.: Brassey's, 2000. ISBN 1-57488-258-9 OCLC 43903491 Caraccilo, Dominic J. The Ready Brigade of the 82nd Airborne in Desert Storm: A Combat Memoir by the Headquarters Company Commander. Jefferson, N.C.: McFarland, 1993. ISBN 0-89950-829-4 OCLC 27265069 Carter, Ross S. Those Devils in Baggy Pants. Cutchogue, NY: Buccaneer Books, 1996.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.